Sarepta added more than 75% in early trading on news that its Duchenne muscular dystrophy (DMD) treatment Exondys 51 has been approved.

New data for Amgen and UCB’s bone drug romosozumab (aka romo) showed it could help lower certain fractures in older women as it awaits an FDA approval decision…

Novartis released updated data for its MS candidate siponimod (aka BAF312) over the weekend which showed it can cut the risk of patients’ disability…

Days after Eli Lilly announced that Richard Gaynor, its SVP of clinical development for its oncology biz, would be retiring, the Big Pharma has announced a…

Novavax saw its shares plummet afterhours yesterday when it announced a late-stage test of its infectious respiratory disease vaccine missed all of its marks…

An influential group of experts from the FDA has said that small cap Spectrum’s experimental bladder cancer med Qapzola (apaziquone) isn’t good enough for…

Roche’s new multiple sclerosis drug has beaten out the aging MS treatment Rebif (interferon beta-1a) in a head-to-head late-stage test as it looks to a…

GlaxoSmithKline and partner Johnson & Johnson have submitted their next-gen IL-6 arthritis med sirukumab to the EMA a month before rivals Regeneron and…